National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No. 7) (No. PB 53 of 2011) (Cth)
PB 53 of 2011
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No. 7)
National Health Act 1953
___________________________________________________________________________
I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated 22 July 2011
FELICITY MCNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________________
1 Name of Instrument
(1)This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No.7).
(2)This Instrument may also be cited as PB 53 of 2011.
2 Commencement
This Instrument commences on 1 August 2011.
3 Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
.
Schedule 1 Amendments
[1] Schedule 1, after entry for Epoetin Alfa in the form Injection 20,000 units in 0.5 mL pre-filled syringe
omit:
| Injection 30,000 units in 0.75 mL pre‑filled syringe | Injection | Eprex 30,000 | JC | EMP | C1957 C3334 | 12 | 5 | D |
[2] Schedule 1, entry for Etanercept
omit from the column headed Responsible Person (all instances):
WX
and substitute (all instances):
PF
[3] Schedule 1, entry for Filgrastim
substitute:
| Filgrastim | Injection 120 micrograms in 0.2 mL single use pre-filled syringe | Injection | Nivestim | HH | EMP | C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 | 20 | 11 | D |
| C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 | ||||||||
| Injection 300 micrograms in 1 mL | Injection | Neupogen | AN | EMP | C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 | 20 | 11 | D |
| Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Neupogen) | Injection | Neupogen | AN | EMP | C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 | 20 | 11 | D |
| Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim) | Injection | Nivestim | HH | EMP | C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 | 20 | 11 | D |
| Injection 480 micrograms in 1.6 mL | Injection | Neupogen | AN | EMP | C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 | 20 | 11 | D |
| Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Neupogen) | Injection | Neupogen | AN | EMP | C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 | 20 | 11 | D |
| Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim) | Injection | Nivestim | HH | EMP | C2912 C2913 C2914 C2915 C2916 C2917 C2918 C2919 C2920 C2921 C2922 C2923 C2924 C2925 C2926 C2927 C2928 C2929 C2930 C3087 C3187 C3357 C3358 C3359 C3360 C3361 C3362 C3363 C3364 C3365 C3366 C3367 C3368 C3369 C3370 C3371 C3372 C3373 C3374 C3375 C3376 C3377 | 20 | 11 | D |
[4] Schedule 1, entry for Infliximab
omit from the column headed Responsible Person:
SH
and substitute:
JC
[5] Schedule 1, entry for Maraviroc
omit from the column headed Responsible Person (all instances):
PF
and substitute (all instances):
VI
[6] Schedule 1, entry for Sirolimus
substitute:
| Sirolimus | Tablet 0.5 mg | Oral | Rapamune | PF | EMP | C1650 C3355 | 200 | 5 | C |
| Tablet 1 mg | Oral | Rapamune | PF | EMP | C1650 C3355 | 200 | 5 | C | |
| Tablet 2 mg | Oral | Rapamune | PF | EMP | C1650 C3355 | 200 | 5 | C | |
| Oral solution 1 mg per mL, 60 mL | Oral | Rapamune | PF | EMP | C1650 C3355 | 200 | 5 | C |
[7] Schedule 2:
after:
| SC | Bayer Australia Ltd | 22 000 138 714 |
omit:
| SH | Schering-Plough Pty Limited | 57 000 235 245 |
[8] Schedule 2:
after:
| VI | ViiV Healthcare Pty Ltd | 46 138 687 448 |
omit:
| WX | Wyeth Australia Pty Limited | 16 000 296 211 |
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0